Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of PHA-739358 administered by a 24-hour IV infusion every 14 days in advanced/metastatic breast, ovarian, colorectal, pancreatic, small cell lung and non small cell lung cancers.

Next Previous
Trial Profile

Phase II study of PHA-739358 administered by a 24-hour IV infusion every 14 days in advanced/metastatic breast, ovarian, colorectal, pancreatic, small cell lung and non small cell lung cancers.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Danusertib (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Nerviano Medical Sciences

    • Most Recent Events

    • 28 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 29 Sep 2015 Status changed from recruiting to active, no longer recruiting. As this trial was started on 2 Feb 2007 and its prospective end date is also passed more over according to the results published in the annals of oncology total 223 patients were enrolled which are close to target accrual (~ planned accrual 232) , hence it seems that trial is closed to accrual.
    • 03 Jul 2012 Additional locations (Belgium, France, Germany, Netherlands, United Kingdom) added as reported by European Clinical Trials Database.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top